NAS:NEO (USA) Also trade in: Germany

NeoGenomics Inc

$ 22.58 0 (-2.25%)
Volume: 1,265,781 Avg Vol (1m): 918,948
Market Cap $: 2.16 Bil Enterprise Value $: 2.25 Bil
P/E (TTM): 376.33 P/B: 6.57
Earnings Power Value 0.51
Net Current Asset Value -0.99
Tangible Book -0.11
Projected FCF 4.39
Median P/S Value 8.75
Graham Number 0
Peter Lynch Value 1.6
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.12
Cash-To-Debt ranked lower than
91.19% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
NEO: 0.12
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 0.31, Max: 10000
Current: 0.12
0.01
10000
Equity-to-Asset 0.61
Equity-to-Asset ranked lower than
66.95% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
NEO: 0.61
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.97, Med: 0.32, Max: 0.75
Current: 0.61
-0.97
0.75
Debt-to-Equity 0.34
Debt-to-Equity ranked lower than
67.68% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
NEO: 0.34
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -16.42, Med: 0.49, Max: 9.87
Current: 0.34
-16.42
9.87
Debt-to-EBITDA 3.20
Debt-to-EBITDA ranked lower than
77.59% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
NEO: 3.2
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -6.54, Med: 3.14, Max: 47.37
Current: 3.2
-6.54
47.37
Interest Coverage 1.53
Interest Coverage ranked lower than
99.39% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
NEO: 1.53
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.56, Med: 1.34, Max: 3.21
Current: 1.53
0.56
3.21
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.95
DISTRESS
GREY
SAFE
Beneish M-Score -2.37
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0.73%
WACC 6.38%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 3.26
Operating Margin ranked higher than
51.24% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
NEO: 3.26
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -8.62, Med: 1.84, Max: 4.78
Current: 3.26
-8.62
4.78
Net Margin % -0.14
Net Margin ranked higher than
52.70% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
NEO: -0.14
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -9.61, Med: -1.35, Max: 3.06
Current: -0.14
-9.61
3.06
ROE % 2.23
ROE ranked higher than
50.00% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
NEO: 2.23
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -75.26, Med: -3.69, Max: 13.15
Current: 2.23
-75.26
13.15
ROA % -0.10
ROA ranked higher than
56.49% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
NEO: -0.1
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -24.84, Med: -0.65, Max: 5.81
Current: -0.1
-24.84
5.81
ROC (Joel Greenblatt) % 11.01
ROC (Joel Greenblatt) ranked higher than
55.21% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
NEO: 11.01
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -36.5, Med: 6.63, Max: 14.65
Current: 11.01
-36.5
14.65
3-Year Total Revenue Growth Rate 40.50
3-Year Revenue Growth Rate ranked higher than
86.81% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
NEO: 22.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 23.65, Max: 140
Current: 22.4
0
140
3-Year Total EBITDA Growth Rate 176.30
3-Year EBITDA Growth Rate ranked higher than
82.58% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
NEO: 140.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 30.45, Max: 140.3
Current: 140.3
0
140.3

» NEO's 30-Y Financials

Financials (Next Earnings Date: 2019-07-24)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NEO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 541714    SIC : 8734
Compare NAS:MEDP NAS:GHDX SHSE:603882 SZSE:300463 NAS:QDEL BSP:DASA3 NAS:MYGN SZSE:300482 SZSE:300244 NAS:BEAT NAS:NTRA NYSE:NVTA BSP:FLRY3 NAS:CDNA TSE:4544 NAS:NRC NSE:LALPATHLAB TSE:4694 OSTO:SECT B NAS:NEOG
Traded in other countries NG9.Germany
Address 12701 Commonwealth Drive, Suite 9, Fort Myers, FL, USA, 33913
NeoGenomics Inc operates a network of genetic testing laboratories in the United States. Its testing services focus on cancer and include cytogenetics, fluorescene in-situ hybridization (FISH), flow cytometry, immunohistochemistry and digital imaging, molecular testing, and pathology consultations. The firm provides both the technical and professional components of its tests to a range of clients, including oncology, dermatology, and urology clinician practices. It also sells its technical services separately for practices that prefer to interpret test results in-house. NeoGenomics also provides services that support pharmaceutical firms and clinical trials, including work on study design and data analysis.

Ratios

Current vs industry vs history
PE Ratio (TTM) 376.33
PE Ratio ranked lower than
100.00% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
NEO: 376.33
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 58.27, Med: 182.96, Max: 1630
Current: 376.33
58.27
1630
Forward PE Ratio 88.50
Forward P/E ranked lower than
95.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
NEO: 88.5
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 376.33
PE without NRI ranked lower than
100.00% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
NEO: 376.33
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 58.27, Med: 182.96, Max: 1630
Current: 376.33
58.27
1630
Price-to-Owner-Earnings 109.07
Price-to-Owner-Earnings ranked lower than
100.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
NEO: 109.07
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 33.02, Med: 113.1, Max: 681.67
Current: 109.07
33.02
681.67
PB Ratio 6.57
PB Ratio ranked lower than
50.61% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
NEO: 6.57
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.02, Med: 7.95, Max: 26.06
Current: 6.57
2.02
26.06
PS Ratio 6.85
PS Ratio ranked higher than
63.04% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
NEO: 6.85
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.02, Med: 2.64, Max: 7.13
Current: 6.85
1.02
7.13
Price-to-Free-Cash-Flow 89.24
Price-to-Free-Cash-Flow ranked lower than
91.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
NEO: 89.24
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 30.88, Med: 69.79, Max: 1456.67
Current: 89.24
30.88
1456.67
Price-to-Operating-Cash-Flow 57.90
Price-to-Operating-Cash-Flow ranked lower than
77.32% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
NEO: 57.9
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 19.04, Med: 41.34, Max: 99999999.99
Current: 57.9
19.04
99999999.99
EV-to-EBIT 223.44
EV-to-EBIT ranked lower than
100.00% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
NEO: 223.44
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -811.9, Med: 75.2, Max: 2788.3
Current: 223.44
-811.9
2788.3
EV-to-EBITDA 65.10
EV-to-EBITDA ranked lower than
71.21% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
NEO: 65.1
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -1566.5, Med: 31, Max: 381.2
Current: 65.1
-1566.5
381.2
EV-to-Revenue 7.31
EV-to-Revenue ranked higher than
64.05% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
NEO: 7.31
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.1, Med: 2.9, Max: 7.5
Current: 7.31
1.1
7.5
PEG Ratio 11.41
PEG Ratio ranked lower than
100.00% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
NEO: 11.41
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 4.93, Med: 8.08, Max: 11.41
Current: 11.41
4.93
11.41
Current Ratio 1.59
Current Ratio ranked lower than
53.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
NEO: 1.59
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 1.23, Max: 4.14
Current: 1.59
0.01
4.14
Quick Ratio 1.46
Quick Ratio ranked higher than
51.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
NEO: 1.46
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 1.14, Max: 3.98
Current: 1.46
0.01
3.98
Days Inventory 17.85
Days Inventory ranked higher than
84.31% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
NEO: 17.85
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 13.99, Med: 17.51, Max: 25.15
Current: 17.85
13.99
25.15
Days Sales Outstanding 97.59
Days Sales Outstanding ranked lower than
66.18% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
NEO: 97.59
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 55.6, Med: 86.62, Max: 179
Current: 97.59
55.6
179
Days Payable 37.25
Days Payable ranked higher than
55.61% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
NEO: 37.25
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 27.58, Med: 43.66, Max: 81.17
Current: 37.25
27.58
81.17

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -6.50
3-Year Share Buyback Rate ranked lower than
56.11% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
NEO: -6.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -166, Med: -11.55, Max: -6
Current: -6.5
-166
-6

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 5.14
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
64.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
NEO: 5.14
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.39, Med: 3.74, Max: 47.43
Current: 5.14
2.39
47.43
Price-to-Median-PS-Value 2.58
Price-to-Median-PS-Value ranked lower than
54.92% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
NEO: 2.58
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.38, Med: 1.11, Max: 100
Current: 2.58
0.38
100
Price-to-Peter-Lynch-Fair-Value 14.11
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
NEO: 14.11
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 6.3, Med: 10.34, Max: 84.5
Current: 14.11
6.3
84.5
Earnings Yield (Joel Greenblatt) % 0.45
Earnings Yield (Greenblatt) ranked higher than
55.47% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
NEO: 0.45
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -8.8, Med: 0.3, Max: 2.4
Current: 0.45
-8.8
2.4
Forward Rate of Return (Yacktman) % 20.64
Forward Rate of Return ranked higher than
88.57% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
NEO: 20.64
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -7.4, Med: -1.9, Max: 21.2
Current: 20.64
-7.4
21.2

More Statistics

Revenue (TTM) (Mil) $ 308.89
EPS (TTM) $ 0.06
Beta 0.76
Volatility % 50
52-Week Range $ 11.05 - 24.84
Shares Outstanding (Mil) 95.47

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y